Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
On January 7, 2026, TheFly reported that Bernstein maintained its Outperform rating. It increased its price objective for Beam Therapeutics Inc. (NASDAQ:BEAM) from $37 to $41. The company's Alpha-1 Antitrypsin Deficiency program received a favorable regulatory update before the change. The latest regulatory action was Bernstein's main stock catalyst for 2026. The company also noted several impending benchmarks, such as the anticipated release of revised AATD data in the first quarter of 2026, which are still important events to keep an eye on through the end of the year. Separately, UBS began covering Beam Therapeutics Inc. (NASDAQ:BEAM) on January 7, 2026, with a $28 price goal and a neutral rating. The launch was a component of a larger coverage action that targeted 22 small- to mid-cap biotechnology firms. As reported by UBS, biotechnology fundamentals are starting to improve after a challenging time, and investor confidence is expected to rebound, setting the industry up for fu
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Cathie Wood quietly buys $7.27 million of popular tech stock [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics (NASDAQ:BEAM) was given a new $41.00 price target on by analysts at Tudor Pickering.MarketBeat
- Beam Therapeutics (NASDAQ:BEAM) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.MarketBeat
- Beam Therapeutics: Pivoting From Platform To Execution Stage [Seeking Alpha]Seeking Alpha
- Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029 [Yahoo! Finance]Yahoo! Finance
BEAM
Earnings
- 11/4/25 - Miss
BEAM
Sec Filings
- 1/30/26 - Form 144
- 1/29/26 - Form 144
- 1/26/26 - Form 4
- BEAM's page on the SEC website